+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Apolipoprotein B/apolipoprotein A1 ratio and non-high-density lipoprotein cholesterol. Predictive value for CHD severity and prognostic utility in CHD patients



Apolipoprotein B/apolipoprotein A1 ratio and non-high-density lipoprotein cholesterol. Predictive value for CHD severity and prognostic utility in CHD patients



Herz 40(Suppl. 1): 1-7



To explore the clinical value of the combination of apolipoprotein B/apolipoprotein A1 (apoB/A1) and non-high-density lipoprotein cholesterol (HDL-C) in evaluating the severity of coronary heart disease (CHD) and in predicting in-hospital CHD events and the long-term prognosis of CHD patients. According to the results of coronary angiography, 826 patients were enrolled and classified into a CHD group (532 cases, including single-branch stenosis group, n = 165; double-branch stenosis group, n = 175;and multi-branch stenosis group, n = 192) and a normal group (294 cases). The serum apoB/apoA1 ratio and non-HDL-C were calculated at baseline. The Gensini score and logistic regression were applied to analyze the association between the apoB/apoA1 ratio, non-HDL-C, and the severity of CHD. Major in-hospital adverse incidents were recorded and follow-up telephone interviews were conducted 3 years after discharge. Both the apoB/apoA1 ratio and non-HDL-C rose with the number of stenotic coronary branches. Only apoB and apoB/apoA1 remained significantly associated with the risk of multi-branches lesions and the Gensini score after adjustment. Patients with combined high levels of apoB/apoA1 and non-HDL-C (N = 50, 43.10 %) suffered from the highest risk of multi-branches lesions. Similarly, patients with combined high levels of apoB/apoA1 and non-HDL-C not only suffered from the highest risk of in-hospital new-onset heart failure and cardiac death (16.38 % vs. 10.35 %), but also had the highest risk of adverse events, angina, myocardial infarction, new-onset heart failure, stroke, and cardiac death after an average 3-year follow-up. The combination of apoB/apoA1 and non-HDL-C is predictive of the severity of CHD, and it could provide more prognostic information than its individual components or other routine lipid profiles.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051601436

Download citation: RISBibTeXText

PMID: 25374385

DOI: 10.1007/s00059-014-4147-5


Related references

Common variation in cholesteryl ester transfer protein: relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio. Journal of Clinical Lipidology 7(1): 56-64, 2013

Influence of cholesteryl ester transfer protein, peroxisome proliferatora“activated receptor , apolipoprotein E, and apolipoprotein A-I polymorphisms on high-density lipoprotein cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-IA-II. 2009

Combined use of apolipoprotein B/apolipoprotein A1 ratio and non-high-density lipoprotein cholesterol before routine clinical lipid measurement in predicting coronary heart disease. Coronary Artery Disease 25(5): 433-438, 2015

Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and Apolipoprotein B among 6382 white women in genome-wide analysis with replication. Circulation. Cardiovascular Genetics 1(1): 21-30, 2010

Influence of cholesteryl ester transfer protein, peroxisome proliferator-activated receptor alpha, apolipoprotein E, and apolipoprotein A-I polymorphisms on high-density lipoprotein cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I:A-II concentrations: the Prospective Epidemiological Study of Myocardial Infarction study. Metabolism: Clinical and Experimental 58(3): 283-289, 2009

Apolipoprotein B/apolipoprotein A-I ratio in relation to the metabolic syndrome, its components, total cholesterol and low-density lipoprotein cholesterol in the population of Georgia. Georgian Medical News 2015(234): 32-39, 2015

Association of the apolipoprotein b/apolipoprotein a-I ratio, metabolic syndrome components, total cholesterol, and low-density lipoprotein cholesterol with insulin resistance in the population of georgia. International Journal of Endocrinology 2014: 925650, 2014

Association of the apolipoprotein B/apolipoprotein A-I ratio and low-density lipoprotein cholesterol with insulin resistance in a Chinese population with abdominal obesity. Acta Diabetologica 49(6): 465-472, 2013

Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. Journal of the American College of Cardiology 52(8): 626-632, 2008

Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines. Circulation 138(3): 244-254, 2018

Coronary artery disease risk predicted by plasma concentrations of high-density lipoprotein cholesterol, apolipoprotein AI, apolipoprotein B, and lipoprotein(a) in a general Chinese population. Clinical Chemistry 39(2): 209-212, 1993

Relation of high-density lipoprotein cholesterol:apolipoprotein a-I ratio to progression of coronary atherosclerosis in statin-treated patients. American Journal of Cardiology 114(5): 681-685, 2014

Phenotypic effects of apolipoprotein structural variation on lipid profiles. III. Contribution of apolipoprotein E phenotype to prediction of total cholesterol, apolipoprotein B, and low density lipoprotein cholesterol in the healthy women study. Arteriosclerosis 10(3): 379-385, 1990

Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. Journal of Clinical Lipidology 7(4): 292-303, 2013

Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism. Journal of Clinical Endocrinology and Metabolism 93(2): 557-564, 2007